Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Cancer Res ; 67(7): 3263-8, 2007 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-17409434

RESUMO

In spite of recent advances in the treatment of colon cancer, multiple liver metastases of colon cancer are still difficult to treat. Some chemotherapeutic regimens have been reported to be efficient, but there is a high risk of side effects associated with these. Here, we show that isoleucine, an essential amino acid, prevents liver metastases in a mouse colon cancer metastatic model. Because isoleucine is a strong inducer of beta-defensin, we first hypothesized that it prevented liver metastases via the accumulation of dendritic cells or memory T cells through up-regulation of beta-defensin. However, neither beta-defensin nor immunologic responses were induced by isoleucine in both mouse livers and spleens. Furthermore, isoleucine prevented liver metastasis in nude mice, which lack T cells and natural killer T cells. Finally, we discovered a novel mechanism of isoleucine: down-regulation of angiogenesis via inhibition of vascular endothelial growth factor, partially through the mammalian target of the rapamycin pathway, independent of hypoxia-inducible factor 1-alpha. Importantly, isoleucine is safe for administration to humans because it does not affect cell viability. Isoleucine could be a novel prophylactic drug for the prevention of liver metastases of colon cancer.


Assuntos
Inibidores da Angiogênese/farmacologia , Neoplasias do Colo/tratamento farmacológico , Isoleucina/farmacologia , Neoplasias Hepáticas/prevenção & controle , Animais , Neoplasias do Colo/irrigação sanguínea , Neoplasias do Colo/metabolismo , Neoplasias do Colo/patologia , Fígado/efeitos dos fármacos , Fígado/imunologia , Neoplasias Hepáticas/irrigação sanguínea , Neoplasias Hepáticas/secundário , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Neovascularização Patológica/tratamento farmacológico , Neovascularização Patológica/patologia , Proteínas Quinases/metabolismo , RNA Mensageiro/antagonistas & inibidores , RNA Mensageiro/biossíntese , RNA Mensageiro/genética , Baço/efeitos dos fármacos , Baço/imunologia , Serina-Treonina Quinases TOR , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Fator A de Crescimento do Endotélio Vascular/biossíntese , Fator A de Crescimento do Endotélio Vascular/genética
2.
Microbes Infect ; 8(11): 2647-56, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16935542

RESUMO

HIV-1 genome has an AU-rich sequence and requires rapid nuclear export by Rev activity to prevent multiple splicing. HIV-1 infection occurs in activated CD4(+) T cells where the decay of mRNAs of cytokines and chemokines is regulated by the binding of AU-rich elements to the mRNA-destabilizing protein tristetraprolin. We here investigated the influence of tristetraprolin on the replication of HIV-1. Treatment of siRNA against tristetraprolin in a latently HIV-1 infected cell line increases HIV-1 production following stimulation. A chloramphenicol acetyltransferase and luciferase assay revealed that exogenous tristetraprolin reduced HIV-1 virion production and in contrast increased the multiply spliced products. Furthermore, quantitative RT-PCR analysis showed tristetraprolin increases the ratio of multiple-spliced RNAs to un-, single-spliced RNA. Moreover, an electrophoretic mobility shift assay showed that tristetraprolin binds to synthesized HIV-1 RNA with AU-rich sequence but not to RNA with less AU sequence. These results suggest that tristetraprolin is a regulator of HIV-1 replication and enhances splicing by direct binding to AU-rich sequence of HIV-1 RNAs.


Assuntos
Genoma Viral , HIV-1/fisiologia , RNA Viral/metabolismo , Tristetraprolina/metabolismo , Replicação Viral , Linhagem Celular , Cloranfenicol O-Acetiltransferase/análise , Cloranfenicol O-Acetiltransferase/genética , Ensaio de Desvio de Mobilidade Eletroforética , Inativação Gênica , HIV-1/genética , Humanos , Luciferases/análise , Luciferases/genética , Ligação Proteica , Splicing de RNA , RNA Interferente Pequeno/metabolismo , RNA Viral/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Tristetraprolina/antagonistas & inibidores
3.
Microbes Infect ; 8(12-13): 2706-14, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16968669

RESUMO

Attenuated recombinant H5N1 influenza virus was constructed to develop a safe H5N1 influenza vaccine. The immunogenicity and protective effect of the vaccine prepared from haemagglutinin-modified recombinant H5N1 influenza virus was evaluated in mice intranasally co-administered with cholera toxin B subunit containing a trace amount of holotoxin (CTB*), synthetic double-stranded RNA, poly (I:C) or chitin microparticles (CMP) as adjuvants. Intranasal administration of recombinant H5 HA split vaccine with CTB* or poly(I:C) and/or CMP elicited an immunological response with both anti-H5 HA IgA in the nasal wash and anti-H5 HA IgG antibody in the serum, and showed a protective against lethal H5N1 A/Hong Kong/483/97 (HK483) infection. We also demonstrated that intranasal co-administration of antigen with both poly (I:C) and CMP enhanced the expression of Toll-like receptor (TLR) 3, TLR7 in the spleen. These results indicate that poly (I:C) and CMP are highly effective as mucosal adjuvants for use with the nasal H5N1 vaccine.


Assuntos
Anticorpos Antivirais/análise , Glicoproteínas de Hemaglutininação de Vírus da Influenza/imunologia , Virus da Influenza A Subtipo H5N1/imunologia , Vacinas contra Influenza/imunologia , Infecções por Orthomyxoviridae/prevenção & controle , Adjuvantes Imunológicos , Administração Intranasal , Animais , Anticorpos Antivirais/sangue , Quitina/imunologia , Toxina da Cólera/imunologia , Modelos Animais de Doenças , Feminino , Glicoproteínas de Hemaglutininação de Vírus da Influenza/genética , Imunidade nas Mucosas , Imunoglobulina A/análise , Imunoglobulina G/sangue , Vacinas contra Influenza/administração & dosagem , Tecido Linfoide/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Microesferas , Mucosa Nasal/imunologia , Infecções por Orthomyxoviridae/virologia , Poli I-C/imunologia , RNA de Cadeia Dupla/imunologia , Baço/imunologia , Receptores Toll-Like/biossíntese , Vacinas de Subunidades Antigênicas/genética , Vacinas de Subunidades Antigênicas/imunologia , Vacinas Sintéticas/genética , Vacinas Sintéticas/imunologia
4.
Cancer Lett ; 189(2): 221-30, 2003 Jan 28.
Artigo em Inglês | MEDLINE | ID: mdl-12490315

RESUMO

Wild type (wt) p21 Bax was cleaved to generate p18 Bax during apoptotic processes by calpain, which was suggested to recognize a certain motif around amino acids 30-33 Phe-Ile-Gln-Asp (FIQD). In the present study, analysis of protein sequencing revealed that the cleavage site was between Gln28 and Gly29. The fragment lacking the NH(2)-terminal amino acids 1-28 (tBax(29)) was more apoptotic than wt Bax. The tBax(29)-induced apoptotic cell death was substantially resistant to Bcl-x(L)-mediated rescue, compared with wt Bax, in spite of the complex formation between these two molecules. Together, the tBax(29) would be valuable for the treatment of tumors with high levels of Bcl-x(L) as well as the understanding of Bax-mediated apoptotic processes.


Assuntos
Apoptose/efeitos dos fármacos , Calpaína/metabolismo , Fragmentos de Peptídeos/farmacologia , Proteínas Proto-Oncogênicas/farmacologia , Adenocarcinoma/patologia , Motivos de Aminoácidos , Linhagem Celular/efeitos dos fármacos , Códon , Neoplasias do Colo/patologia , Humanos , Rim/embriologia , Mutagênese Sítio-Dirigida , Proteínas Proto-Oncogênicas/química , Proteínas Proto-Oncogênicas/metabolismo , Proteínas Proto-Oncogênicas c-bcl-2/farmacologia , Especificidade por Substrato , Células Tumorais Cultivadas/efeitos dos fármacos , Proteína X Associada a bcl-2 , Proteína bcl-X
5.
Biochem Biophys Res Commun ; 340(3): 807-14, 2006 Feb 17.
Artigo em Inglês | MEDLINE | ID: mdl-16380083

RESUMO

AU-rich elements (AREs) in the 3'-untranslated region of mRNAs promote rapid decay of the mRNAs for certain cytokines, including that encoding granulocyte-macrophage colony-stimulating factor (GM-CSF). We show that an RNA molecule based on the ARE of GM-CSF mRNA is cleaved between U and A residues in the presence of bovine serum albumin of which cleavage effect is attenuated by acetylation. Furthermore, the expression of RNA molecule containing the ARE of GM-CSF mRNA in human cell lines was increased by inhibition of histone deacetylase activity and attenuation of Dicer expression. These findings suggest that degradation of mRNAs containing an ARE might be regulated by positive charge of polypeptides and Dicer.


Assuntos
Endorribonucleases/fisiologia , Fator Estimulador de Colônias de Granulócitos e Macrófagos/fisiologia , RNA Helicases/fisiologia , RNA/química , Ribonuclease III/fisiologia , Regiões 3' não Traduzidas , Animais , Sequência de Bases , Sítios de Ligação , Bovinos , Linhagem Celular Tumoral , Citocinas/metabolismo , RNA Helicases DEAD-box , Endorribonucleases/química , Fator Estimulador de Colônias de Granulócitos e Macrófagos/química , Fator Estimulador de Colônias de Granulócitos e Macrófagos/metabolismo , Células HeLa , Histonas/metabolismo , Humanos , Immunoblotting , Luciferases/metabolismo , Dados de Sequência Molecular , Peptídeos/química , Estrutura Secundária de Proteína , Estrutura Terciária de Proteína , RNA Helicases/química , RNA Mensageiro/metabolismo , RNA Interferente Pequeno/metabolismo , Proteínas Recombinantes de Fusão/química , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Ribonuclease III/química , Albumina Sérica/metabolismo , Fatores de Tempo
6.
J Med Virol ; 78(7): 954-63, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16721854

RESUMO

A safe and effective adjuvant is necessary to enhance mucosal immune responses for the development of an inactivated intranasal influenza vaccine. The present study demonstrated the effectiveness of surf clam microparticles (SMP) derived from natural surf clams as an adjuvant for an intranasal influenza vaccine. The adjuvant effect of SMP was examined when co-administered intranasally with inactivated A/PR8 (H1N1) influenza virus hemagglutinin vaccine in BALB/c mice. Administration of the vaccine with SMP induced a high anti-PR8 haemagglutinin (HA)-specific immunoglobulin A (IgA) response in the nasal wash and immunoglobulin G (IgG) response in the serum, resulting in protection against both nasal-restricted infection and lethal lung infection by A/PR8 virus. In addition, administration of SMP with A/Yamagata (H1N1), A/Beijing (H1N1), or A/Guizhou (H3N2) vaccine conferred complete protection against A/PR8 virus challenge in the nasal infection model, suggesting that SMP adjuvanted vaccine can confer cross-protection against variant influenza viruses. The use of SMP is suggested as a new safe and effective mucosal adjuvant for nasal vaccination against influenza virus infection.


Assuntos
Adjuvantes Imunológicos/administração & dosagem , Bivalves/imunologia , Vacinas contra Influenza/administração & dosagem , Influenza Humana/imunologia , Influenza Humana/prevenção & controle , Adjuvantes Imunológicos/isolamento & purificação , Administração Intranasal , Animais , Encéfalo , Feminino , Glicoproteínas de Hemaglutininação de Vírus da Influenza/administração & dosagem , Humanos , Imunidade nas Mucosas , Vírus da Influenza A/imunologia , Injeções , Injeções Intraperitoneais , Camundongos , Camundongos Endogâmicos BALB C , Infecções por Orthomyxoviridae/imunologia , Infecções por Orthomyxoviridae/prevenção & controle , Segurança , Estômago , Linfócitos T/imunologia , Vacinas de Produtos Inativados/administração & dosagem
7.
Exp Cell Res ; 304(2): 518-30, 2005 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-15748896

RESUMO

Type I interferon (IFN)-induced antitumor action is due in part to apoptosis, but the molecular mechanisms underlying IFN-induced apoptosis remain largely unresolved. In the present study, we demonstrate that IFN-beta induced apoptosis and the loss of mitochondrial membrane potential (delta psi m) in the murine CH31 B lymphoma cell line, and this was accompanied by the up-regulation of CD95, but not CD95-ligand (CD95-L), tumor necrosis factor (TNF), or TNF-related apoptosis-inducing ligand (TRAIL). Pretreatment with anti-CD95-L mAb partially prevented the IFN-beta-induced loss of delta psi m, suggesting that the interaction of IFN-beta-up-regulated CD95 with CD95-L plays a crucial role in the induction of fratricide. IFN-beta induced a sustained activation of c-Jun NH2-terminal kinase 1 (JNK1), but not extracellular signal-regulated kinases (ERKs). The IFN-beta-induced apoptosis and loss of delta psi m were substantially compromised in cells overexpressing a dominant-negative form of JNK1 (dnJNK1), and it was slightly enhanced in cells carrying a constitutively active JNK construct, MKK7-JNK1 fusion protein. The IFN-beta-induced up-regulation of CD95 together with caspase-8 activation was also abrogated in the dnJNK1 cells while it was further enhanced in the MKK7-JNK1 cells. The levels of cellular FLIP (c-FLIP), competitively interacting with caspase-8, were down-regulated by stimulation with IFN-beta but were reversed by the proteasome inhibitor lactacystin. Collectively, the IFN-beta-induced sustained activation of JNK mediates apoptosis, at least in part, through up-regulation of CD95 protein in combination with down-regulation of c-FLIP protein.


Assuntos
Apoptose/efeitos dos fármacos , Linfócitos B/efeitos dos fármacos , Interferon beta/farmacologia , Proteínas Quinases JNK Ativadas por Mitógeno/efeitos dos fármacos , Linfoma de Células B/tratamento farmacológico , Receptor fas/metabolismo , Animais , Antineoplásicos/farmacologia , Apoptose/imunologia , Linfócitos B/imunologia , Linfócitos B/metabolismo , Proteína Reguladora de Apoptosis Semelhante a CASP8 e FADD , Citocinas/efeitos dos fármacos , Citocinas/metabolismo , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/fisiologia , Ativação Enzimática/efeitos dos fármacos , Ativação Enzimática/fisiologia , Proteína Ligante Fas , Humanos , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , Proteínas Quinases JNK Ativadas por Mitógeno/genética , Proteínas Quinases JNK Ativadas por Mitógeno/metabolismo , Células Jurkat , Linfoma de Células B/imunologia , Linfoma de Células B/metabolismo , Glicoproteínas de Membrana/metabolismo , Potenciais da Membrana/efeitos dos fármacos , Potenciais da Membrana/fisiologia , Camundongos , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Mutação/genética , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/fisiologia
8.
J Virol ; 79(5): 2910-9, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15709010

RESUMO

The mucosal adjuvant effect of synthetic double-stranded RNA polyriboinosinic polyribocytidylic acid [poly(I:C)] against influenza virus was examined under intranasal coadministration with inactivated hemagglutinin (HA) vaccine in BALB/c mice and was shown to have a protective effect against both nasal-restricted infection and lethal lung infection. Intranasal administration of vaccine from PR8 (H1N1) with poly(I:C) induced a high anti-HA immunoglobulin A (IgA) response in the nasal wash and IgG antibody response in the serum, while vaccination without poly(I:C) induced little response. Intracerebral injection confirmed the safety of poly(I:C). In addition, we demonstrated that administration of poly(I:C) with either A/Beijing (H1N1) or A/Yamagata (H1N1) vaccine conferred complete protection against PR8 challenge in this mouse nasal infection model, suggesting that poly(I:C) possessed cross-protection ability against variant viruses. To investigate the mechanism of the protective effect of poly(I:C), mRNA levels of Toll-like receptors and cytokines were examined in the nasal-associated lymphoid tissue after vaccination or virus challenge. Intranasal administration of HA vaccine with poly(I:C) up-regulated expression of Toll-like receptor 3 and alpha/beta interferons as well as Th1- and Th2-related cytokines. We propose that poly(I:C) is a new effective intranasal adjuvant for influenza virus vaccine.


Assuntos
Vacinas contra Influenza/administração & dosagem , Infecções por Orthomyxoviridae/prevenção & controle , Poli I-C/administração & dosagem , Administração Intranasal , Animais , Anticorpos Antivirais/biossíntese , Anticorpos Antivirais/sangue , Reações Cruzadas , Citocinas/genética , Feminino , Glicoproteínas de Hemaglutininação de Vírus da Influenza/administração & dosagem , Imunidade nas Mucosas , Imunoglobulina A/biossíntese , Imunoglobulina G/sangue , Fatores Imunológicos/administração & dosagem , Vírus da Influenza A/imunologia , Vírus da Influenza A/patogenicidade , Injeções Intraventriculares , Glicoproteínas de Membrana/genética , Camundongos , Camundongos Endogâmicos BALB C , Infecções por Orthomyxoviridae/imunologia , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Receptores de Superfície Celular/genética , Segurança , Receptor 3 Toll-Like , Receptores Toll-Like , Regulação para Cima
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA